Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Chemotherapy: Irinotecan or etoposide as front-line therapy for SCLC?

× No keyword cloud information.

9 in total

1. Randomized phase III trial comparing irinotecan/cisplatin with etoposide/cisplatin in patients with previously untreated extensive-stage disease small-cell lung cancer.

Authors: Nasser Hanna; Paul A Bunn; Corey Langer; Lawrence Einhorn; Troy Guthrie; Thaddeus Beck; Rafat Ansari; Peter Ellis; Michael Byrne; Mark Morrison; Subramanian Hariharan; Benjamin Wang; Alan Sandler
Journal: J Clin Oncol Date: 2006-05-01 Impact factor: 44.544

2. Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer.

Authors: Kazumasa Noda; Yutaka Nishiwaki; Masaaki Kawahara; Shunichi Negoro; Takahiko Sugiura; Akira Yokoyama; Masahiro Fukuoka; Kiyoshi Mori; Koshiro Watanabe; Tomohide Tamura; Seiichiro Yamamoto; Nagahiro Saijo
Journal: N Engl J Med Date: 2002-01-10 Impact factor: 91.245

3. Randomized phase II trial comparing amrubicin with topotecan in patients with previously treated small-cell lung cancer: North Japan Lung Cancer Study Group Trial 0402.

Authors: Akira Inoue; Shunichi Sugawara; Koichi Yamazaki; Makoto Maemondo; Toshiro Suzuki; Kazunori Gomi; Shingo Takanashi; Chieko Inoue; Minoru Inage; Hiroshi Yokouchi; Hiroshi Watanabe; Toumei Tsukamoto; Yasuo Saijo; Osamu Ishimoto; Fumihiro Hommura; Toshihiro Nukiwa
Journal: J Clin Oncol Date: 2008-10-14 Impact factor: 44.544

4. Japanese-US common-arm analysis of paclitaxel plus carboplatin in advanced non-small-cell lung cancer: a model for assessing population-related pharmacogenomics.

Authors: David R Gandara; Tomoya Kawaguchi; John Crowley; James Moon; Kiyoyuki Furuse; Masaaki Kawahara; Satoshi Teramukai; Yuichiro Ohe; Kaoru Kubota; Stephen K Williamson; Oliver Gautschi; Heinz Josef Lenz; Howard L McLeod; Primo N Lara; Charles Arthur Coltman; Masahiro Fukuoka; Nagahiro Saijo; Masanori Fukushima; Philip C Mack
Journal: J Clin Oncol Date: 2009-05-26 Impact factor: 44.544

5. Phase III trial of irinotecan/cisplatin compared with etoposide/cisplatin in extensive-stage small-cell lung cancer: clinical and pharmacogenomic results from SWOG S0124.

Authors: Primo N Lara; Ronald Natale; John Crowley; Heinz Josef Lenz; Mary W Redman; Jane E Carleton; James Jett; Corey J Langer; J Philip Kuebler; Shaker R Dakhil; Kari Chansky; David R Gandara
Journal: J Clin Oncol Date: 2009-04-06 Impact factor: 44.544

6. Phase III study of oral compared with intravenous topotecan as second-line therapy in small-cell lung cancer.

Authors: John R Eckardt; Joachim von Pawel; Jean-Louis Pujol; Zsolt Papai; Elisabeth Quoix; Andrea Ardizzoni; Ruth Poulin; Alaknanda J Preston; Graham Dane; Graham Ross
Journal: J Clin Oncol Date: 2007-05-20 Impact factor: 44.544

Review 7. Recurrent small cell lung cancer: update.

Authors: Bonnie S Glisson
Journal: Semin Oncol Date: 2003-02 Impact factor: 4.929

8. Irinotecan plus carboplatin versus oral etoposide plus carboplatin in extensive small-cell lung cancer: a randomized phase III trial.

Authors: Andreas Hermes; Bengt Bergman; Roy Bremnes; Lars Ek; Sverre Fluge; Christer Sederholm; Stein Sundstrøm; Lars Thaning; Jan Vilsvik; Ulf Aasebø; Sverre Sörenson
Journal: J Clin Oncol Date: 2008-09-10 Impact factor: 44.544

Review 9. Can UGT1A1 genotyping reduce morbidity and mortality in patients with metastatic colorectal cancer treated with irinotecan? An evidence-based review.

Authors: Glenn E Palomaki; Linda A Bradley; Michael P Douglas; Katherine Kolor; W David Dotson
Journal: Genet Med Date: 2009-01 Impact factor: 8.822

9 in total

1 in total

Review 1. Combinatorial strategies for the induction of immunogenic cell death.

Authors: Lucillia Bezu; Ligia C Gomes-de-Silva; Heleen Dewitte; Karine Breckpot; Jitka Fucikova; Radek Spisek; Lorenzo Galluzzi; Oliver Kepp; Guido Kroemer
Journal: Front Immunol Date: 2015-04-24 Impact factor: 7.561

1 in total